EA201391701A1 - Назальные тестостероновые гели с контролируемым высвобождением, способы перназального введения и предварительно заполненные многодозные аппликаторные системы для перназального введения - Google Patents

Назальные тестостероновые гели с контролируемым высвобождением, способы перназального введения и предварительно заполненные многодозные аппликаторные системы для перназального введения

Info

Publication number
EA201391701A1
EA201391701A1 EA201391701A EA201391701A EA201391701A1 EA 201391701 A1 EA201391701 A1 EA 201391701A1 EA 201391701 A EA201391701 A EA 201391701A EA 201391701 A EA201391701 A EA 201391701A EA 201391701 A1 EA201391701 A1 EA 201391701A1
Authority
EA
Eurasian Patent Office
Prior art keywords
testosterone
low
introduction
levels
gels
Prior art date
Application number
EA201391701A
Other languages
English (en)
Russian (ru)
Inventor
Уэйн Креппнер
Шивон Фогарти
Вернер Обереггер
Пол Хосе Пьер Мари Маэс
Original Assignee
Тримел Биофарма Срл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тримел Биофарма Срл filed Critical Тримел Биофарма Срл
Publication of EA201391701A1 publication Critical patent/EA201391701A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA201391701A 2011-05-15 2012-05-15 Назальные тестостероновые гели с контролируемым высвобождением, способы перназального введения и предварительно заполненные многодозные аппликаторные системы для перназального введения EA201391701A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161486324P 2011-05-15 2011-05-15
US201161486634P 2011-05-16 2011-05-16
PCT/IB2012/001127 WO2012156822A1 (en) 2011-05-15 2012-05-15 Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration

Publications (1)

Publication Number Publication Date
EA201391701A1 true EA201391701A1 (ru) 2014-04-30

Family

ID=46579248

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201391701A EA201391701A1 (ru) 2011-05-15 2012-05-15 Назальные тестостероновые гели с контролируемым высвобождением, способы перназального введения и предварительно заполненные многодозные аппликаторные системы для перназального введения

Country Status (16)

Country Link
EP (3) EP3977982A1 (cg-RX-API-DMAC7.html)
JP (9) JP6152092B2 (cg-RX-API-DMAC7.html)
KR (10) KR102568894B1 (cg-RX-API-DMAC7.html)
CN (4) CN103796636B (cg-RX-API-DMAC7.html)
AR (2) AR089553A1 (cg-RX-API-DMAC7.html)
AU (11) AU2012257492A1 (cg-RX-API-DMAC7.html)
BR (2) BR112013029332A2 (cg-RX-API-DMAC7.html)
CA (3) CA3034552C (cg-RX-API-DMAC7.html)
DK (1) DK2714006T3 (cg-RX-API-DMAC7.html)
EA (1) EA201391701A1 (cg-RX-API-DMAC7.html)
ES (1) ES2859784T3 (cg-RX-API-DMAC7.html)
IL (2) IL229400A0 (cg-RX-API-DMAC7.html)
MX (4) MX395212B (cg-RX-API-DMAC7.html)
PL (1) PL2714006T3 (cg-RX-API-DMAC7.html)
WO (2) WO2012156822A1 (cg-RX-API-DMAC7.html)
ZA (2) ZA201309265B (cg-RX-API-DMAC7.html)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757388B2 (en) 2011-05-13 2017-09-12 Acerus Pharmaceuticals Srl Intranasal methods of treating women for anorgasmia with 0.6% and 0.72% testosterone gels
US20130045958A1 (en) 2011-05-13 2013-02-21 Trimel Pharmaceuticals Corporation Intranasal 0.15% and 0.24% testosterone gel formulations and use thereof for treating anorgasmia or hypoactive sexual desire disorder
AR086400A1 (es) 2011-05-13 2013-12-11 Trimel Pharmaceuticals Corp Formulaciones en gel intranasal de testosterona en dosis de menor potencia y uso de las mismas para el tratamiento de la anorgasmia o el trastorno de deseo sexual hipoactivo
EA201391701A1 (ru) * 2011-05-15 2014-04-30 Тримел Биофарма Срл Назальные тестостероновые гели с контролируемым высвобождением, способы перназального введения и предварительно заполненные многодозные аппликаторные системы для перназального введения
US8971800B2 (en) * 2011-05-31 2015-03-03 Qualcomm Incorporated Methods and apparatus for improving NFC activation and data exchange reporting mechanisms
PL2782584T3 (pl) 2011-11-23 2021-12-13 Therapeuticsmd, Inc. Naturalne skojarzone hormonalne formulacje i terapie zastępcze
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150297733A1 (en) * 2012-11-14 2015-10-22 Trimel Biopharma Srl Controlled release topical testosterone formulations and methods
US20140171918A1 (en) * 2012-12-14 2014-06-19 Bioject, Inc. Use of a novel subcutaneous needle-free technique to deliver testosterone in hypogonadal men
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11744838B2 (en) 2013-03-15 2023-09-05 Acerus Biopharma Inc. Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event
US11160751B2 (en) * 2013-10-07 2021-11-02 Antares Pharma, Inc. Hematocrit modulation through needle assisted jet injection of testosterone
US10238662B2 (en) * 2014-02-19 2019-03-26 Antares Pharma, Inc. Needle assisted jet injection administration of testosterone compositions
MX2016014281A (es) 2014-05-22 2017-02-22 Therapeuticsmd Inc Formulaciones y terapias de reemplazo de combinación de hormonas naturales.
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
WO2016123317A1 (en) * 2015-01-28 2016-08-04 Prometheon Pharma, Llc Topical formulations of growth factors
CN113633434B (zh) * 2015-06-29 2025-07-11 莱拉医药公司 用于治疗鼻窦炎的可植入支架
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
BR102015020878B1 (pt) * 2015-08-28 2019-08-27 F B M Ind Farmaceutica Ltda formulação farmacêutica nasal de testosterona e “kit” em forma de cartela de dispositivos nasais unitários para aplicação de monodose de testosterona.
ES2949053T3 (es) * 2016-01-07 2023-09-25 Viramal Ltd Composiciones de gel para administración transdérmica para maximizar las concentraciones de fármaco en el estrato córneo y suero, y métodos de uso de las mismas
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
MX2018012967A (es) 2016-04-25 2019-03-06 Koska Family Ltd Sistema de suministro medico.
MX392668B (es) * 2016-06-02 2025-03-24 Acerus Labs Inc Composiciones nasales de cannabidiol
EP3463375A1 (en) 2016-06-03 2019-04-10 M Et P Pharma AG Nasal pharmaceutical compositions with a porous excipient
ES2948282T3 (es) * 2017-01-20 2023-09-07 M et P Pharma AG Composiciones farmacéuticas nasales para reducir los riesgos de la exposición a contaminantes atmosféricos
US10764951B2 (en) * 2017-06-17 2020-09-01 Lg Electronics Inc. Registration method of user terminal in wireless communication system and apparatus therefor
KR102639913B1 (ko) 2017-11-17 2024-02-23 코스카 패밀리 리미티드 유체 전달 매니폴드를 위한 시스템 및 방법
MX2020005437A (es) * 2017-11-27 2020-08-27 Aska Pharm Co Ltd Preparacion en polvo para administracion nasal.
FI3710012T3 (fi) * 2018-02-02 2025-09-01 Acerus Biopharma Inc Testosteroniterapiamenetelmät
WO2019175290A1 (en) 2018-03-13 2019-09-19 Beckley Canopy Therapeutics Limited Cannabis or cannabis derived compositions for promoting cessation of chemical dependence
CN108771622B (zh) * 2018-07-11 2022-01-07 尹振图 一种自闭式针形滴嘴及眼药水瓶
BR112021007877A2 (pt) 2018-10-26 2021-08-03 Viramal Limited composição em gel mucoadesiva
US20200170962A1 (en) 2018-11-30 2020-06-04 F. Markus Leweke Nasal cannabidiol compositions
EP3659583B1 (en) 2018-11-30 2023-06-07 Viramal Limited A method of preparing a gelling agent, the gelling agent obtained thereby, and the use of said gelling agent
CN113365635A (zh) * 2018-12-14 2021-09-07 阿克罗斯生物制药公司 睾酮的活性酯衍生物、组合物和其用途
USD1052082S1 (en) 2020-06-01 2024-11-19 Koska Family Limited Sealed fluid container
CN112121049B (zh) * 2020-08-28 2022-02-01 嘉兴市第一医院 顺式阿曲库铵在制备治疗男性性腺功能减退症的药物中的应用
MX2023005822A (es) * 2020-11-19 2023-05-31 Acousia Therapeutics Gmbh Composicion de gel no acuoso.
GB202307501D0 (en) * 2023-05-19 2023-07-05 Lawley Pharmaceuticals Pty Ltd Process for preparing dispensable testosterone cream

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4082881A (en) * 1976-12-23 1978-04-04 E. R. Squibb & Sons, Inc. Topical and other type pharmaceutical formulations containing isosorbide carrier
DE4214953C2 (de) 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
US5756071A (en) 1992-06-03 1998-05-26 Arrowdean Limited Method for nasally administering aerosols of therapeutic agents to enhance penetration of the blood brain barrier
DE4405898A1 (de) * 1994-02-18 1995-08-24 Schering Ag Transdermale therapeutische Systeme enthaltend Sexualsteroide
US5576071A (en) 1994-11-08 1996-11-19 Micron Technology, Inc. Method of reducing carbon incorporation into films produced by chemical vapor deposition involving organic precursor compounds
JP2000514065A (ja) * 1997-07-03 2000-10-24 アルザ コーポレイション ドラッグデリバリーディバイスとその製造法
DE69840426D1 (de) * 1997-11-10 2009-02-12 Strakan Int Ltd Penetrationsfördernde und irritationsvermindernde Systeme mit Testosteron
US20040198706A1 (en) * 2003-03-11 2004-10-07 Carrara Dario Norberto R. Methods and formulations for transdermal or transmucosal application of active agents
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
DE10064950A1 (de) * 2000-12-23 2002-07-11 Impetus Ag Basel Thixotropes Nasenspray
JP2005505587A (ja) * 2001-10-12 2005-02-24 シーエヌエス・インコーポレーテッド 含水性の点鼻ゲル及びその塗布装置
MY139721A (en) * 2002-04-19 2009-10-30 Cpex Pharmaceuticals Inc Pharmaceutical composition
IL152575A (en) * 2002-10-31 2008-12-29 Transpharma Medical Ltd A skin-to-skin transmission system of water-insoluble drugs
DK1670433T3 (da) * 2003-10-10 2012-03-12 Ferring Bv Transdermal farmaceutisk formulering til mindskelse af hudrester
ATE319426T1 (de) 2003-11-11 2006-03-15 Mattern Udo Nasenformulierung mit kontrollierter freisetzung von sexualhormonen
MX2007006908A (es) * 2004-12-09 2007-08-03 Bayer Healthcare Ag Estabilizacion de esteres de glucocorticoides con acidos.
WO2006128255A1 (en) * 2005-06-03 2006-12-07 Acrux Dds Pty Ltd Method and composition for transdermal drug delivery
EP1790343A1 (en) * 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmaceuticals formulations and uses thereof in the treatment of female sexual dysfunction
CN101099742A (zh) * 2006-07-06 2008-01-09 上海富海科申药业有限公司 能够减少皮肤刺激的睾酮凝胶制剂
ATE496617T1 (de) * 2006-10-04 2011-02-15 M & P Patent Ag Abgabesystem mit gesteuerter freisetzung zur nasalen anwendung von neurotransmittern
AU2008231781B2 (en) * 2007-03-23 2012-09-20 Besins Healthcare Luxembourg Sarl Compositions and method for treating pediatric hypogonadism
EP2191833B1 (en) * 2007-09-20 2013-02-13 Shiseido Company, Ltd. Transdermally absorbable preparation
HUE027440T2 (en) * 2007-11-13 2016-10-28 Curadis Gmbh C-19 steroids for specific medical applications
GB0807605D0 (en) * 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
EA201391701A1 (ru) * 2011-05-15 2014-04-30 Тримел Биофарма Срл Назальные тестостероновые гели с контролируемым высвобождением, способы перназального введения и предварительно заполненные многодозные аппликаторные системы для перназального введения

Also Published As

Publication number Publication date
JP2020079257A (ja) 2020-05-28
AU2024216312A1 (en) 2024-10-24
ZA201309265B (en) 2016-01-27
AU2020210227A1 (en) 2020-08-20
KR20210135003A (ko) 2021-11-11
BR112013029336A2 (pt) 2020-08-11
WO2012156822A1 (en) 2012-11-22
JP2022105175A (ja) 2022-07-12
KR102568894B1 (ko) 2023-08-21
AU2012257492A1 (en) 2013-12-19
WO2012156820A1 (en) 2012-11-22
JP2014515038A (ja) 2014-06-26
IL229400A0 (en) 2014-01-30
JP2020073469A (ja) 2020-05-14
CA2836398A1 (en) 2012-11-22
JP2021001206A (ja) 2021-01-07
JP7017254B2 (ja) 2022-02-08
JP2022078222A (ja) 2022-05-24
AU2017204182A1 (en) 2017-07-20
EP2709588A1 (en) 2014-03-26
KR20140033408A (ko) 2014-03-18
WO2012156820A9 (en) 2014-02-20
BR112013029332A2 (pt) 2021-06-01
CN109481394B (zh) 2023-05-05
MX2013013369A (es) 2014-10-17
KR20140045400A (ko) 2014-04-16
MX395212B (es) 2025-03-21
ZA201309264B (en) 2015-09-30
DK2714006T3 (da) 2021-03-15
AU2019203067A1 (en) 2019-05-23
PL2714006T4 (pl) 2021-08-16
CN103813784A (zh) 2014-05-21
AU2017203470A1 (en) 2017-06-22
KR20200118228A (ko) 2020-10-14
AU2022202402A1 (en) 2022-05-12
KR20200028503A (ko) 2020-03-16
KR102088038B1 (ko) 2020-03-13
AU2020267162A1 (en) 2020-12-03
AU2019201618A1 (en) 2019-04-18
JP2017160204A (ja) 2017-09-14
KR20230041081A (ko) 2023-03-23
PL2714006T3 (pl) 2021-08-16
CN103796636B (zh) 2019-04-05
EP2714006A1 (en) 2014-04-09
JP6152092B2 (ja) 2017-06-28
CA3034552C (en) 2023-02-07
CA2836398C (en) 2021-12-14
CN109481394A (zh) 2019-03-19
AR086409A1 (es) 2013-12-11
KR20210029849A (ko) 2021-03-16
CA2836405A1 (en) 2012-11-22
ES2859784T3 (es) 2021-10-04
MX2019003340A (es) 2019-07-04
MX374398B (es) 2025-03-06
KR20240162608A (ko) 2024-11-15
AU2012257490A1 (en) 2013-12-19
KR20190117803A (ko) 2019-10-16
AU2020267162B2 (en) 2022-06-09
KR20190006194A (ko) 2019-01-17
EP2714006B1 (en) 2020-12-09
BR112013029336B1 (pt) 2021-11-30
JP2018199701A (ja) 2018-12-20
JP2014513716A (ja) 2014-06-05
CN103796636A (zh) 2014-05-14
MX2013013388A (es) 2014-09-15
EP2709588B1 (en) 2021-08-25
JP6594924B2 (ja) 2019-10-23
CA2836405C (en) 2021-09-07
CN110613679A (zh) 2019-12-27
IL229401A0 (en) 2014-01-30
AU2019203400A1 (en) 2019-08-01
EP3977982A1 (en) 2022-04-06
MX2020008599A (es) 2022-08-31
MX363561B (es) 2019-03-27
AR089553A1 (es) 2014-09-03
CA3034552A1 (en) 2012-11-22

Similar Documents

Publication Publication Date Title
EA201391701A1 (ru) Назальные тестостероновые гели с контролируемым высвобождением, способы перназального введения и предварительно заполненные многодозные аппликаторные системы для перназального введения
NZ704579A (en) Nasal stimulation devices and methods
MY188825A (en) High-concentration monoclonal antibody formulations
EA201290865A1 (ru) Применение леводопы, карбидопы и энтакапона для лечения болезни паркинсона
MX2015002239A (es) Formulacion oftalmica de lipido polioxilo o de acido graso polioxilo y tratamiento de padecimientos oculares.
EA201400002A1 (ru) Способы лечения заболеваний сетчатки
EA201391006A1 (ru) Гипотоническая водная композиция с пониженным содержанием хлора и с или без фосфолипидов
MX365007B (es) Uso de acido lipasa lisosomal para tratar la dificiencia de acido lipasa lisosomal en pacientes.
MX2016009306A (es) Reequilibrado inmunologico epicutaneo.
MX2015012322A (es) Uso de levocetirizina y montelukast en el tratamiento de trastornos autoinmunes.
WO2014184576A3 (en) Delivery of a therapeutic agent to the cerebral cortex by administering a viral vector by convection enhanced diffusion into the white matter of the brain
MX2018008299A (es) Metodos para administrar hepcidina.
MX2015008676A (es) Formulaciones de nanoparticulas de metadichol, liquidas y en gel.
CL2018003346A1 (es) Uso de hidrolizado de colágeno para preparar un medicamento contra la pérdida degenerativa de masa muscular (sarcopenia) y para mejorar la fuerza muscular (divisional de solicitud 3326-2015).
MX2015005038A (es) Formulaciones de levodopa para el alivio rapido de la enfermedad de parkinson.
EA201690903A1 (ru) Лечение глаукомы с использованием лаквинимода
MX2019007236A (es) Metodos de administracion de hepcidina.
Izhbul'dina Changes in the hemostasis system and free-radical lipid oxidation in the acute stage of ischemic stroke in patients on neuroprotection treatment
HK1196261A (en) Controlled release nasal testosterone gels, methods and pre-filled multi-dose applicator systems for pernasal administration
NZ705229A (en) Pharmaceutical formulations containing ipidacrine and their use for the treatment of disorders of potency and disorders of other forms of sexual activity
EA201290972A1 (ru) Способы уменьшения симптомов у субъектов с применением лекарственных форм для однократного введения с постепенно снижающимися скоростями высвобождения
EA201600229A1 (ru) Бис(5-амино-1,4-диоксо-1,2,3,4-тетрагидрофталазин-2-ил)цинк, способ его получения, фармацевтическая композиция на его основе, лечебные средства на его основе, способ лечения кожных заболеваний и способ лечения гастрита
Guler Valproic acid
EA201990676A1 (ru) Лечение остеоартрита
UA96878C2 (ru) Средство для лечения заболеваний сердечно-сосудистой системы и регулирования метаболических процессов